Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast Cancer - Episode 4

Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC

,

The panel examines how resistance mutations influence the effectiveness of subsequent treatment lines and delves into the process of selecting later-line therapies based on follow-up next-generation sequencing results.

EP. 1: Biomarker Testing Best Practices in HR+/HER2- mBC
EP. 2: First-Line Treatment Options in HR+/HER2- and Challenges with Treatment Resistance
EP. 3: Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway
Now Viewing
EP. 4: Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC
  1. How does the identification of resistance mechanisms impact your clinical decision making? Do resistance mutations impact efficacy of later-line treatments?
    1. How does treatment resistance after 1L treatment create challenges in selecting 2L therapies?
    2. How do you weigh efficacy, toxicity, and patient quality of life when selecting 2L treatment?
  2. On the other hand, how might the identification of actionable mutations allow for optimalselection of targeted treatment options in later-lines?
    1. How are targeted therapies directed at actionable mutations changing the treatment paradigm?